Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer

NCT04420754 is registered in ClinicalTrials.gov with AffyImmune Therapeutics, Inc. as lead sponsor.

NCT NCT04420754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04420754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer
Lead sponsor
AffyImmune Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 28, 2020
Completion date
August 4, 2030
Enrollment
70 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer, relapsed/refractory poorly differentiated thyroid cancer